Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible staphylococcus aureus endocarditis

Clinical Infectious Diseases

Volumn 58, Issue 12, 2014, Pages 1668-1675

  Cervera, Carlos ^a   Castañeda, Ximena ^a   De La Maria, Cristina Garcia ^b   Del Rio, Ana ^a   Moreno, Asunción ^a   Soy, Dolors ^b   Pericas, Juan Manuel ^a   Falces, Carlos ^b   Armero, Yolanda ^b   Almela, Manel ^b   Ninot, Salvador ^b   Pare, Juan Carlos ^b   Mestres, Carlos A ^b   Gatell, Jose M ^a   Marco, Francesc ^b   Miro, Jose M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

cloxacillin; left sided endocarditis; methicillin susceptible Staphylococcus aureus; mortality; vancomycin minimal inhibitory concentration

Indexed keywords

CLOXACILLIN; DAPTOMYCIN; GENTAMICIN; OXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSCESS; ADULT; AGE; AGED; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EMBOLISM; EPSILOMETER TEST; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; TERTIARY CARE CENTER; DRUG EFFECTS; ENDOCARDITIS, BACTERIAL; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOXACILLIN; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; VANCOMYCIN;

EID: 84901787375     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu183     Document Type: Article

References (25)

1. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169:463-73.
2. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41:507-14.
3. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: A consequence of medical progress. JAMA 2005; 293:3012-21.
4. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
5. Hidayat LK, Hsu DI, Quist R, Shriner KA,Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
6. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycinminimuminhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71.
7. Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycin- intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355-66.
8. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
9. Aguado JM, San-Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 2011; 17:1099-102.
10. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2013; 19:1163-8.
11. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-434.
12. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
13. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
14. Federspiel JJ, Stearns SC, Peppercorn AF, Chu VH, Fowler VG Jr. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Arch Intern Med 2012; 172:363-5.
15. Miller CE, Batra R, Cooper BS, et al. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis 2012; 54:591-600.
16. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 2006; 4:479-90.
17. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-7.
18. Marco F, de la Maria CG, Armero Y, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2538-43.
19. Miro JM, García de la María C, Castañeda X, et al. Adjusted vancomycin (VAN) dosage to reach an AUC/MIC index ≥400 did not improve the outcome of experimental endocarditis (EE) caused by methicillinresistant Staphylococcus aureus (MRSA) strains with different VAN MICs [abstract #A-610]. In: Program and abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. 9-12 September, 2012.
20. Fowler VG Jr, Nelson CL, McIntyre LM, et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007; 196:738-47.
21. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, et al. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis 2011; 204:704-13.
22. Gill SR, McIntyre LM, Nelson CL, et al. Potential associations between severity of infection and the presence of virulence-associated genes in clinical strains of Staphylococcus aureus. PLoS One 2011; 6: e18673.
23. DeLeo FR, Kennedy AD, Chen L, et al. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci USA 2011; 108:18091-6.
24. Beenken KE, Mrak LN, Griffin LM, et al. Epistatic relationships between sarA and agr in Staphylococcus aureus biofilm formation. PLoS One 2010; 5:e10790.
25. Viedma E, Sanz F, Orellana MA, et al. Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillinsusceptible Staphylococcus aureus causing bacteraemia. J Antimicrob Chemother 2014; 69:51-8.